Guggenheim Boosts Merck Price Target to $170

Guggenheim has maintained its 'Buy' rating for Merck & Co (MRK) and increased its price target to $170.00, a 16.44% boost from the previous target of $146.00.

This upward adjustment reflects Guggenheim analyst Vamil Divan's confidence in Merck's future performance, aligning with the positive assessments of other analysts such as Wells Fargo and Goldman Sachs.

MERCK is a major player in the drug manufacturing industry, with a market capitalization of approximately $362.32 billion and a robust vaccine portfolio led by Keytruda, its immuno-oncology platform.